Alzai Health Corp. News Releases

Alzai Health Corp. Announces Marketing Services Agreement

Mon, 17 Aug 2026 06:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - August 17, 2026) - Alzai Health Corp. (TSXV: ALZI) (the "Company" or "ALZAI") announces that it has entered into a services agreement dated August 12, 2026 (the "Services Agreement") with Euro Digital Media Ltd. ("Euro Digital") (address: 71-75 Shelton Street, Covent Garden, London, UK WC2H 9JQ) pursuant to which Euro Digital will provide market awareness and digital marketing services to the Company.Under the terms of the Services Agreement, Euro Digital will...

ALZAI and Linus Health Explore AI-Driven Collaborations Aimed at Early Identification of Alzheimer's Disease Risk and Cognitive Impairment

Tue, 11 Aug 2026 06:00:00 -0400

Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - August 11, 2026) - ALZAI Health Corp. (TSXV: ALZI) is pleased to announce that it has entered into a Memorandum of Understanding (MOU) with Linus Health, an AI-driven brain health company focused on early detection and proactive intervention. The companies intend to explore opportunities to use their complementary technologies to support earlier identification and assessment of Alzheimer's disease risk and cognitive impairment, as...

ALZAI Health Corp. Secures Exclusive Global License for AI-Driven Liver Disease Risk Identification Technology

Mon, 20 Jul 2026 06:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 20, 2026) - ALZAI Health Corp. (TSXV: ALZI) ("ALZAI" or the "Company"), is pleased to announce that it has entered into an exclusive worldwide license agreement (the "Agreement") with MOR Research Applications Ltd. ("MOR"), the technology transfer company of Clalit Health Services and Yeda Research, the technology transfer company of the Weizmann Institute of Science and Development Co. Ltd. ("Yeda"), for proprietary artificial intelligence-driven liver...

ALZAI Health Corp. Announces Validation of Its AI-Driven Alzheimers Disease Risk Screening Solution on Large-Scale U.S. Patient Data

Mon, 06 Jul 2026 06:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 6, 2026) - ALZAI Health Corp. (TSXV: ALZI) ("ALZAI" or the "Company"), is pleased to announce the validation of its proprietary artificial intelligence-driven Alzheimer's disease risk identification models using a large-scale U.S. longitudinal healthcare dataset, representing a significant milestone in the Company's potential U.S. commercialization.The validation demonstrated that ALZAI's risk-stratification models achieved performance on-par with...

Alzai Health Corp. Signs Strategic U.S. Commercialization Agreement with Centauri Health Solutions to Advance AI-Driven Alzheimer's Risk Identification

Thu, 02 Jul 2026 06:49:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 2, 2026) - ALZAI Health Corp. (TSXV: ALZI) ("ALZAI" or the "Company"), is pleased to announce that it has entered into a strategic teaming agreement (the "Agreement") with Centauri Health Solutions ("Centauri"), a leading U.S. healthcare technology company serving 60 million members through advanced mission-critical technology, data intelligence, and engagement solutions delivered to U.S. health plans, healthcare providers and health systems. Under the...